Emerging Therapeutic Targets Shape Testing and Treatment Decisions in SCLC and NSCLC
October 31st 2023Apar Kishor Ganti, MD, discusses molecular targets to test for in lung cancer; treatment approaches for small cell lung cancer; and immunotherapy options for patients with metastatic non–small cell lung cancer in the frontline setting and beyond.
Read More
EMA Validates Application for Frontline Nivolumab Plus Chemo in Advanced Urothelial Cancer
October 30th 2023The European Medicines Agency has validated a type II variation application for the first-line combination of nivolumab and cisplatin-based chemotherapy for adult patients with unresectable or metastatic urothelial carcinoma.
Read More
Expanding Immunotherapy Armamentarium Propels Personalized HCC Treatment Approaches
October 28th 2023Richard Kim, MD, discusses the range of systemic treatment options available for patients with unresectable hepatocellular carcinoma and the importance of assessing patients for high-risk disease criteria before beginning any systemic treatment.
Read More
FDA Grants Fast Track Designation to ONCT-534 for Relapsed/Refractory mCRPC
October 27th 2023The FDA has granted fast track designation to the dual-acting androgen receptor inhibitor ONCT-534 for the treatment of patients with relapsed/refractory, metastatic castration-resistant prostate cancer that is resistant to approved androgen receptor pathway inhibitors.
Read More
Bezuclastinib Plus Sunitinib Shows Encouraging Safety and Efficacy Profile in R/R Second-Line GIST
October 25th 2023The combination of bezuclastinib and sunitinib had a tolerable safety profile and demonstrated early signals of clinical activity in patients with gastrointestinal stromal tumor.
Read More
Frontline Sobuzoxane Plus Etoposide and Rituximab is Safe and Effective in Older DLBCL Population
October 23rd 2023The combination of sobuzoxane and etoposide plus rituximab prolonged survival and showcased a tolerable safety profile in patients with previously untreated diffuse large B-cell lymphoma aged 80 years and older.
Read More
Sotorasib Plus Panitumumab Extends PFS in Refractory KRAS G12C+ mCRC
October 22nd 2023Treatment with combinations using sotorasib at multiple dose levels and panitumumab led to improved progression-free survival vs standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.
Read More
Neoadjuvant Pembrolizumab Plus Chemotherapy Boosts pCR in ER+/HER2– Breast Cancer
October 20th 2023Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.
Read More
Novel KRAS G12C Inhibitor Reflects Research Advances in NSCLC and CRC
October 19th 2023David S. Hong, MD, and David Sommerhalder, MD, discuss the unmet needs for patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) that prompted the initiation of the RMC-6291-001 trial; the key efficacy and safety findings with RMC-6291 in patients with NSCLC and CRC; and potential next steps for this agent.
Read More
HR+/HER2– Metastatic Breast Cancer Treatment Developments Continue to Unfold
October 19th 2023Alison K. Conlin, MD, discusses patient characteristics that drive second-line treatment decisions for patients with HR-positive, HER2-negative metastatic breast cancer; remaining needs for patients with HR-positive, HER2-negative disease; and the evolving role of oral selective estrogen receptor degraders in patients with ESR1-mutated disease.
Read More
Newer-Generation JAK Inhibitors Expand Myelofibrosis Treatment Paradigm
October 19th 2023Anthony M. Hunter, MD, discusses the roles for pacritinib, momelotinib, and fedratinib in patients with myelofibrosis; treatment sequencing with newer-generation JAK inhibitors after ruxolitinib; and the importance of having several treatment options in the second-line setting and beyond.
Read More
Individualized Treatment Selection and Sequencing Enhances Bladder and Prostate Cancer Management
October 18th 2023Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.
Read More
The Arsenal of Metastatic Breast Cancer Imaging Modalities Continues to Expand
October 6th 2023Rena D. Callahan, MD, discusses the current standards for breast cancer imaging modalities, the complexities of using bone biopsy, and the importance of continuing to study nonstandard imaging modalities to increase the accessibility of breast cancer imaging for metastatic disease.
Read More
Daily Adaptive Radiotherapy Delivers Improved Efficacy and Safety Outcomes in HNSCC
October 4th 2023Daily adaptive radiotherapy with 1-mm planning target volume margins is feasible in patients with head and neck squamous cell carcinoma and was associated with improved dosimetric parameters compared with standard radiotherapy.
Read More
Multiple Myeloma Call-to-Action Plan Seeks to Ignite Widespread, Patient-Focused Change
October 3rd 2023Faith E. Davies, MD, discusses the overarching goals of the Multiple Myeloma Call-to-Action, unmet needs that this plan seeks to alleviate, and ways in which all medical professionals could adopt these tenets into their practice to achieve global change in the care of patients with multiple myeloma.
Read More
Overall response rates with bispecific antibody monotherapy in patients with extramedullary relapsed/refractory multiple myeloma were lower than ORRs observed across all patients with relapsed/refractory multiple myeloma included in a systematic review evaluating the efficacy of this class of agents in this difficult-to-treat population.
Read More
Phase 1 Trial Seeks to Determine the Role for Upfront Uproleselan in AML
September 27th 2023Naval G. Daver, MD, discusses the rationale for investigating uproleselan combinations in patients with acute myeloid leukemia, the current role of quizartinib in patients with FLT3-ITD–mutated disease, and potential future directions with both these agents in the AML field.
Read More
Research Demonstrates the Importance of Effective Frontline Regimens for High-Risk Multiple Myeloma
September 27th 2023Saad Z. Usmani, MD, MBA, FACP, discusses key points from his presentation at the 2023 SOHO Annual Meeting on frontline treatment of patients with high-risk myeloma, including the characteristics of patients with disease at high risk of recurrence, current treatment approaches, and ongoing research aiming to address unmet needs for this subset of patients.
Read More
Novel Sequencing Strategies May Expand Localized and Metastatic Breast Cancer Treatment Landscapes
September 27th 2023Jairam Krishnamurthy, MD, FACP, highlights the benefits of neoadjuvant therapy in early-stage HER2-positive breast cancer, treatment considerations for patients with HER2-negative disease who have progressed on an initial CDK4/6 inhibitor, and ongoing research that may address unmet needs in the field.
Read More
Luspatercept Broadens Lower-Risk MDS Treatment Landscape
September 25th 2023Guillermo Garcia-Manero, M, discusses key efficacy and safety findings from the COMMANDS trial; the significance of the FDA approval of luspatercept in patients with lower-risk MDS; and considerations for bringing this agent into clinical practice.
Read More
Continued CRC Research Informs Later-Line Disease Management
September 21st 2023Howard S. Hochster, MD, highlights key updates in CRC research and management from the 2023 ASCO Annual Meeting, including findings from the phase 2/3 PROSPECT trial, long-term follow-up data from the phase 3 PRODIGE 23 trial, and results of the phase 3 NeoCol study.
Read More
FCR Retains Curative Potential in Young Patients With Favorable CLL Biology
September 20th 2023John Seymour, AM, MBBS, FRACP, FAHMS, PhD, discusses the characteristics of patients with CLL who may benefit from FCR, how genetic testing can provide key insights into individual patient disease patterns, and treatment sequencing options after progression on FCR.
Read More
Cabozantinib Is Safe and Tolerable in Sorafenib-Intolerant HCC
September 16th 2023The phase 2 ACTION trial, which evaluated the safety of second-line cabozantinib in patients with hepatocellular carcinoma who were intolerant to first-line sorafenib or who received agents other than sorafenib in the first line, did not meet its safety futility criteria, allowing the trial to continue.
Read More